Showing results (1191-1200 of 2,357) with videos related to
Sort By:
Pageof 236
Clinical Neuropharmacology|October 12, 1999
"Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case reportG Defazio, M De Mari, R De Salvia, et al.Clinical Neuropharmacology|October 6, 2000
Mexiletine in the treatment of torticollis and generalized dystoniaC Lucetti, A Nuti, G Gambaccini, et al.Clinical Neuropharmacology|October 6, 2000
Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeysA Hadj Tahar, L Grégoire, E Bangassoro, et al.Clinical Neuropharmacology|October 6, 2000
Effect and time course of deep brain stimulation of the globus pallidus and subthalamus on motor features of Parkinson's diseaseA Hristova, K Lyons, A I Tröster, et al.Clinical Neuropharmacology|October 6, 2000
Protease inhibitor-induced carbamazepine toxicityA Berbel Garcia, A Latorre Ibarra, J Porta Etessam, et al.Clinical Neuropharmacology|January 12, 2001
Visual hallucinations induced by deep brain stimulation in Parkinson's diseaseN J Diederich, F Alesch, C G GoetzClinical Neuropharmacology|January 1, 1983
Naloxone reversal of 5-hydroxytryptamine tachyphylaxis in humansF Sicuteri, P L Del Bianco, B Anselmi, et al.Clinical Neuropharmacology|February 27, 1999
Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's diseaseA Napolitano, P Del Dotto, L Petrozzi, et al.Clinical Neuropharmacology|February 27, 1999
The effect of deprenyl treatment on directional and velocity control of arm movement in patients with early stages of Parkinson's diseaseN Giladi, S Honigman, S HochermanClinical Neuropharmacology|January 1, 1985
Clinical and subclinical thiamine deficiency in clinical practiceM W Carney, S BarryPageof 236